^
Association details:
Biomarker:CD34 underexpression
Cancer:Diffuse Large B Cell Lymphoma
Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

THE PROGNOSTIC ROLE OF CD34 ANGIOGENESIS MARKER IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Published date:
06/12/2020
Excerpt:
Overall response on RCHOP immunotherapy was in 42 (87.5%) patients with low-level CD34 expression...CD34 expression status on microenvironment cells can be an important prognostic factor in therapy response achievement and overall survival in patients with DLBCL.